<DOC>
	<DOCNO>NCT00003687</DOCNO>
	<brief_summary>RATIONALE : Different drug formulation combination drug may help patient chronic pain live comfortably . It yet know regimen effective chronic pain . PURPOSE : Randomized phase III trial compare effectiveness different morphine formulation without dextromethorphan treat chronic pain patient advance cancer .</brief_summary>
	<brief_title>Treatment Chronic Pain Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare analgesic efficacy two formulation morphine ( Statex SR versus MS-Contin ) patient require morphine treatment chronic cancer pain . - Compare effect 2 formulation morphine total analgesic consumption , sleep disturbance , sleep nausea , responses different type pain , toxic effect experience two treatment group . - Compare effect coadministration morphine dextromethorphan versus morphine placebo pain control respective patient group ( phase B ) . - Compare effect morphine dextromethorphan placebo total analgesic consumption , sleep disturbance , sleep nausea , responses different type pain , toxic effect two treatment group ( phase B ) . OUTLINE : This randomize , double-blind , parallel-group , multicenter study . Patients stratified stabilization dose ( le 120 mg/day v great 120 mg/day morphine ) institution phase A , neuropathic pain ( yes v ) phase B . - Phase A : Patients randomize receive oral morphine one two formulation ( MS Contin Statex SR ) every 12 hour 7 day . - Phase B : Eligible patient phase A take 2 breakthrough dos analgesic per day previous 2 day re-randomized receive dose escalate oral dextromethorphan capsule placebo every 4 hour , oral morphine tablet every 12 hour 14 day . - Phase C : All patient fulfil entry criterion end phase A time phase B may receive compassionate use morphine tablet 90 day . Patients complete pain diary twice day treatment . PROJECTED ACCRUAL : A total 120 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven advanced cancer chronic pain Cancer pain require strong opioids average pain score less 6/10 visual analog scale within last 24 hour Pain manage stable maintenance dose MSContin formulation morphine least 2 day 2 breakthrough immediate release morphine dose per 24 hour Pain expect control stable adequate total daily dose sustain release morphine first 7 day study PATIENT CHARACTERISTICS : Age : 16 Performance status : Not specify Life expectancy : At least 2 month Hematopoietic : Not specify Hepatic : SGOT SGPT great 3 time upper limit normal ( ULN ) No liver disease Renal : Creatinine great 2 time ULN No kidney failure Pulmonary : No clinically significant respiratory depression No severe obstructive airway disease Other : Fluent English French No known hypersensitivity allergy study medication component multiple drug allergy Normal cognition define Folstein MiniMental State Questionnaire ( least 24/30 correct ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 14 day since prior chemotherapy Endocrine therapy : Concurrent steroid allow Radiotherapy : At least 14 day since prior analgesic radiotherapy Surgery : Not specify Other : At least 3 month since prior investigational agent At least 1 month since prior clinical study No concurrent analgesic morphine No concurrent medication contain dextromethorphan Concurrent antidepressant medication allow Concurrent nonsteroidal antiinflammatory drug allow At least 14 day since prior monoamine oxidase ( MAO ) inhibitors No concurrent MAO inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>monoclonal gammopathy undetermined significance</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>isolated plasmacytoma bone</keyword>
	<keyword>extramedullary plasmacytoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>untreated hairy cell leukemia</keyword>
	<keyword>progressive hairy cell leukemia , initial treatment</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>pain</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>AIDS-related peripheral/systemic lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
	<keyword>primary systemic amyloidosis</keyword>
	<keyword>non-Hodgkin lymphoma pregnancy</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>